Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 6
2004 2
2005 8
2006 5
2007 7
2008 8
2009 7
2010 4
2011 9
2012 10
2013 12
2014 12
2015 8
2016 8
2017 22
2018 20
2019 11
2020 19
2021 23
2022 20
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
[Light chain amyloidosis].
Hegenbart U, Aus dem Siepen F, Schönland S. Hegenbart U, et al. Inn Med (Heidelb). 2023 Sep;64(9):842-847. doi: 10.1007/s00108-023-01568-0. Epub 2023 Aug 4. Inn Med (Heidelb). 2023. PMID: 37540260 Review. German.
Prognosis and Staging of AL Amyloidosis.
Dittrich T, Kimmich C, Hegenbart U, Schönland SO. Dittrich T, et al. Among authors: hegenbart u. Acta Haematol. 2020;143(4):388-400. doi: 10.1159/000508287. Epub 2020 Jun 22. Acta Haematol. 2020. PMID: 32570242 Free article. Review.
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.
Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. Palladini G, et al. Among authors: hegenbart u. Blood Cancer J. 2023 Jan 25;13(1):19. doi: 10.1038/s41408-023-00789-8. Blood Cancer J. 2023. PMID: 36697388 Free PMC article.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Muchtar E, et al. Among authors: hegenbart u. J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10. J Clin Oncol. 2023. PMID: 36215675 Free PMC article.
Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S, Hegenbart U, Schoder R, Steinhardt M, Papathanasiou M, Rassaf T, Thimm A, Hagenacker T, Naser E, Duhrsen U, Reinhardt HC, Kortum M, Agis H, Schonland S, Carpinteiro A. Oubari S, et al. Among authors: hegenbart u. Haematologica. 2024 Jan 1;109(1):220-230. doi: 10.3324/haematol.2023.283325. Haematologica. 2024. PMID: 37439344 Free PMC article.
Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, Huart A, Javaugue V, Pascal L, Royer B, Talbot A, Gounot R, Hegenbart U, Schonland S, Karlin L, Harel S, Kastritis E, Bridoux F, Jaccard A, Arnulf B. Forgeard N, et al. Among authors: hegenbart u. Blood. 2024 Feb 22;143(8):734-737. doi: 10.1182/blood.2023022937. Blood. 2024. PMID: 38096365 No abstract available.
201 results